Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Gene Therapy
Scientists at German Cancer Research Center describe research in gene therapy
September 2nd, 2008
Research findings, 'Generation of efficient human blood progenitor-targeted recombinant adeno-associated viral vectors (AAV) by applying an AAV random peptide library on primary human hematopoietic progenitor cells,' are discussed in a new report. "Currently standard recombinant adeno-associated virus serotype 2(rAAV2)-based vectors lack the efficiency for gene transfer into primary human CD34(+) peripheral blood progenitor cells (PBPC). An advancement in vector development now allows the generation of rAAV capsid mutants that offer higher target cell efficiency and specificity," investigators in Heidelberg, Germany report. "To increase the gene transfer into...
Source: Cancer Weekly (2008-09-02)
|
